Visit
Thanks for your feedback, this will help us improve our content for you!
Thank for your feedback, this will help us improve our content for you!
Dr Jean-Jacques Kiladjian discusses the results of the follow up to the RESPONSE study of ruxolitinib versus standard therapy for the treatment of patients with polycythemia vera.
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter